Table 3.

2nd generation antibodies and their key patents

Second generation mAb INN (Trade name, Company)	Target	First generation mAb INN (Trade name, Company)	Alleged improvement	Key patent
Ofatumumab (Arzerra, GlaxoSmithKline)	CD20	Rituximab (Rituxan, Genentech)	Humanized	US7850962
GA101 (Roche)	CD20	Rituximab (Rituxan, Genentech)	Glycoengineered for better ADCC	EP1692182
Golimumab (Simponi, Centocor)	Tumor necrosis factor α	Adalimumab (Humira, Abbbott)	Unclear (Centocor advertises better dosing frequency, but patent claims specific affinity to tumor necrosis factor α)	US7070775
Motavizumab (Medimmune)	Respiratory syncytial virus	Palivizumab (Synagis, Medimmune)	Higher target affinity (50–70 fold)	US740851

ADCC, antibody-dependent cell-mediated cytotoxicity; CD, cluster of differentiation; INN, international non-proprietary name